TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05666245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Protective Equipment (PPE) - Under High Air Hygiene
Description: Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Intervention - Under High Air Hygiene
Description: No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C.
Study: NCT04676867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalcetrapib
Description: Dalcetrapib 300 mg Film-Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalcetrapib
Description: Dalcetrapib 300 mg Film-Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalcetrapib
Description: Dalcetrapib 300 mg Film-Coated Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study: NCT04495868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacteriostatic Normal Saline
Description: A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic Normal Saline
Description: A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study: NCT05666245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Protective Equipment (PPE) - Under Low Air Hygiene
Description: Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Intervention - Under Low Air Hygiene
Description: No intervention~Low air hygiene is achieved with minimal ventilation.
Study: NCT04521387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma injection in the painful area of humeral epicondyle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection in the painful area of humeral epicondyle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Injection
Description: Hyaluronic acid injection in the painful area of humeral epicondyle.
Study: NCT04495868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine
Description: A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study: NCT04521387

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Saline injection in the painful area of humeral epicondyle.
Study: NCT04836390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
Description: Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
Study: NCT06521073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17).
Study: NCT05867290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful music-listening with sleep hygiene
Description: 5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
Study: NCT05961449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cycling control
Description: The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
Study: NCT05651633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride 5mg/g
Description: 1-2 drops up to six times daily for a maximum of 7 days
Study: NCT05931679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Headset
Description: A VR headset will be used for participants in the Interactive VR and 360 degree video groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Headset
Description: A VR headset will be used for participants in the Interactive VR and 360 degree video groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Theatre-based simulation
Description: Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
Study: NCT05217433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive leaf extract
Description: The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
Study: NCT05951010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
Study: NCT04976166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: More informed and detailed education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Shared decision making

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: education as usual
Study: NCT06226766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN033 Injection
Description: JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
Study: NCT05908162

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
Study: NCT05496166

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
Description: Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
Description: Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
Study: NCT06326164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kinesio-taping.
Description: A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kinesio-taping.
Description: A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A designed physiotherapy program.
Description: The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
Study: NCT05540015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction by cutting and rotary tools
Description: Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction by erbium laser with wavelength 2.94 nm
Description: Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
Study: NCT05495009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care+virtual reality glasses
Description: At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
Study: NCT05970146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Stellate ganglion block
Description: Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unilateral cervical epidural
Description: Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
Study: NCT05618782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEVI-04
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEVI-04
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEVI-04
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:
Description: Placebo dose intravenous infusion
Study: NCT04790825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth scaling and root planing (FMSRP)
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth scaling and root planing (FMSRP)
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
Study: NCT05875194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation (tDCS)
Description: 2mA, over the left dlPFC (10-20 position F3), duration 15 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active transcranial direct current stimulation (tDCS)
Description: 2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
Study: NCT05220163

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD
Description: It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert
Description: A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xpert
Description: A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
Study: NCT05840627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice
Description: Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
Study: NCT04651699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
Study: NCT05763836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
Description: Intravenous ibuprofen infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
Description: Intravenous ibuprofen infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalp nerve block
Description: Scalp nerves blocked by using local anesthetics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp nerve block
Description: Scalp nerves blocked by using local anesthetics
Study: NCT05027932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IN Placebo
Description: The placebo will be normal saline in two syringes administered IN.
Study: NCT05458674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: taknen intravenously
Study: NCT05027932

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IN Placebo
Description: The placebo will be normal saline in two syringes administered IN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IM Placebo
Description: The placebo will be normal saline in a syringe administered IM.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IM Placebo
Description: The placebo will be normal saline in a syringe administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-1357
Description: BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-1357
Description: BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
Study: NCT05458674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: taken intravenously